Is Intellia Therapeutics, Inc. overvalued or undervalued?

As of 14 March 2017, Intellia Therapeutics, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 1.07, an EV to Sales ratio of 8.19, and a ROCE of -169.74%.
In comparison to its peers, Intellia's P/E ratio is significantly negative at -2.02, while Axsome Therapeutics, Inc. also shows a risky valuation with a P/E of -20.23. Krystal Biotech, Inc. is categorized as expensive with a P/E of 25.47, highlighting the disparity in valuations within the sector. Notably, Intellia's stock has underperformed significantly over the past year, with a return of -61.89% compared to the S&P 500's 10.26%, reinforcing the perception of overvaluation.